Ongoing Surveillance After Active Therapy
Download
Report
Transcript Ongoing Surveillance After Active Therapy
Ongoing Surveillance After
Active Breast Cancer Therapy
EVIDENCE-BASED GUIDELINES
A N D R E C O M M E N D A TI O N S
ASCO 2006 Update
Breast Cancer Follow-Up Guidelines
Experts from the American Society of Clinical
Oncology (ASCO) get together every few years to
review the latest trials and evidence related to
ongoing surveillance for breast cancer survivors
Most recent meeting in 2006 produced a number of
guidelines, included in these slides
Main
finding
“The evidence supports regular
history, physical examination,
and mammography as the
cornerstone of appropriate breast
cancer follow-up.”
J L Khatcheressian, A C Wolff, T J Smith, E Grunfeld, H B Muss, VG.
Vogel, F Halberg, M R. Somerfield, and N E Davidson. American Society
of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and
Management Guidelines in the Adjuvant Setting. Journal of Clinical
Oncology 2006. 24:5091-5097.
Recommendations for Physical Examinations
Breast self-examination
All women should be counseled to perform
monthly breast self-examination.
History/physical examination
Every 3 to 6 months for the first 3 years
after primary therapy; every 6 to 12 months
for years 4 and 5; then annually.
Pelvic examination
Regular gynecologic follow-up is
recommended for all women. Patients who
receive tamoxifen should be advised to
report any vaginal bleeding to their
physicians.
J L Khatcheressian, A C Wolff, T J Smith, E Grunfeld, H B Muss, VG. Vogel, F Halberg, M R. Somerfield, and N E Davidson. American Society of
Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting. Journal of Clinical Oncology
2006. 24:5091-5097.
Breast Self-Examination
2006 ASCO Guidelines
U.S. Preventive Services
Task Force Guidelines
Recommend doctors to
In 2009, released
teach women how to do
monthly selfexaminations for
follow-up
J L Khatcheressian, A C Wolff, T J Smith, E Grunfeld, H B Muss,
VG. Vogel, F Halberg, M R. Somerfield, and N E Davidson.
American Society of Clinical Oncology 2006 Update of the Breast
Cancer Follow-Up and Management Guidelines in the Adjuvant
Setting. Journal of Clinical Oncology 2006. 24:5091-5097.
recommendations
against teaching
monthly self-exams for
screening
No specific
recommendations for
breast cancer follow-up
Screening for Breast Cancer. USPSTF November 2009.
http://www.uspreventiveservicestaskforce.org/uspstf/usp
sbrca.htm
ASCO Guidelines on Mammograms
First post-treatment mammogram 1 year after the
initial mammogram (leading to diagnosis)
No earlier than 6 months after radiation therapy
After the first year, mammograms every 6 months or
one year
J L Khatcheressian, A C Wolff, T J Smith, E Grunfeld, H B Muss, VG. Vogel, F Halberg, M R. Somerfield, and N E
Davidson. American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management
Guidelines in the Adjuvant Setting. Journal of Clinical Oncology 2006. 24:5091-5097.
What is not
recommended
for routine
follow-up?
Routine blood
tests
Imaging studies
Tumor markers
Complete Blood
Counts and liver
function tests are not
recommended.
Chest x-ray, bone
scans, liver
ultrasound, CT scans,
FDG-PET scans, and
breast MRI are not
recommended.
CA 15-3, CA 27.29,
and CEA are not
recommended.
J L Khatcheressian, A C Wolff, T J Smith, E Grunfeld, H B Muss, VG. Vogel, F Halberg, M R. Somerfield,
and N E Davidson. American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and
Management Guidelines in the Adjuvant Setting. Journal of Clinical Oncology 2006. 24:5091-5097.
The Evidence
Trials showing no difference in overall survival or
disease-free survival between:
Those followed with intensive imaging and lab tests
Those followed with routine clinical visits and mammography
No evidence that breast MRI improves outcomes like
survival when used as routine follow-up in breast
cancer survivors without symptoms
Evidence to show that additional imaging can result
in unnecessary surgical procedures
J L Khatcheressian, A C Wolff, T J Smith, E Grunfeld, H B Muss, VG. Vogel, F Halberg, M R. Somerfield, and N E Davidson. American Society of
Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting. Journal of Clinical Oncology
2006. 24:5091-5097.
Italy
A study looked at intensive diagnostic follow-up after
treatment of primary breast cancer in breast cancer
clinics around Italy.
1243 participants
Patients in two treatment groups had physical
examination and mammography
Patients of the intensive follow-up group also had
chest X-ray and bone scan every 6 months
No significant difference in 5-year overall mortality
observed between the two follow-up groups
M. Rosselli Del Turco, D. Palli, A. Cariddi, S. Ciatto, P. Pacini, V. Distante. Intensive diagnostic follow-up after treatment of primary breast cancer. A
randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA. 1994 May 25; 271(20): 1593–1597.
GIVIO Trial
1320 patients from 26 hospitals in Italy were
randomly assigned to two groups:
intensive surveillance (including bone scan, liver echography,
chest X-rays, and laboratory tests)
control regimen in which patients were seen by their
physicians at the same frequency but only clinically indicated
tests were performed
The study found no significant difference between
the two groups in survival after an average of 6 years
No significant difference in time to detection of
recurrence
Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO
Investigators. Jama. 1994;271:1587–92.
Breast MRI
MRI is the most sensitive breast imaging tool (88-
100%)
Sensitivity = the % of positive cases identified correctly
Expensive and only moderate specificity (37-70%)
Specificity = the % of negative cases identified correctly
MRI is most valuable when conventional imaging is
unable to detect the presence or extent of a
malignancy, not in routine use
J L Khatcheressian, A C Wolff, T J Smith, E Grunfeld, H B Muss, VG. Vogel, F Halberg, M R. Somerfield, and N E Davidson. American Society of
Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting. Journal of Clinical Oncology
2006. 24:5091-5097.
Caveats
The ASCO guidelines are voluntary
They do not apply to all women
They do not stand in the place of physician judgment
More complex clinical situations call for more
sensitive tests
J L Khatcheressian, A C Wolff, T J Smith, E Grunfeld, H B Muss, VG. Vogel, F Halberg, M R. Somerfield, and N E Davidson. American Society of
Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting. Journal of Clinical
Oncology 2006. 24:5091-5097.
Where to Read More
ASCO and USPSTF Guidelines
http://jco.ascopubs.org/content/24/31/5091.full.pdf
http://www.uspreventiveservicestaskforce.org/uspstf/uspsbrca.htm
Studies
Impact of follow-up testing on survival and health-related quality of life in
breast cancer patients. A multicenter randomized controlled trial. The GIVIO
Investigators. Jama. 1994;271:1587–92.
http://www.ncbi.nlm.nih.gov/pubmed/8182811
M. Rosselli Del Turco, D. Palli, A. Cariddi, S. Ciatto, P. Pacini, V. Distante.
Intensive diagnostic follow-up after treatment of primary breast cancer. A
randomized trial. National Research Council Project on Breast Cancer followup. JAMA. 1994 May 25; 271(20): 1593–1597.
http://www.ncbi.nlm.nih.gov/pubmed/7848404